Seeking Alpha EN

MariMed Non-GAAP EPS of $2.20 beats by $2.21, revenue of $41.7M beats by $0.9M

Mar 11, 2026 &03101111202631; 21:10 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

MariMed delivered strong Q3 results with non-GAAP EPS of $2.20 significantly beating expectations by $2.21, while revenue of $41.7M exceeded estimates by $0.9M. This substantial earnings beat demonstrates operational efficiency and robust demand in the cannabis sector.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

MRMD

MRMDStock

Expected to rise

Strong earnings beat with EPS exceeding expectations by $2.21 and revenue beat of $0.9M indicates operational excellence and market strength

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider initiating or adding to long positions on MariMed given the substantial earnings beat. Monitor for potential upside momentum in the near term, with attention to guidance and sector-wide cannabis regulatory developments.

KEY SIGNALS

Significant EPS beat ($2.21 above expectations)Revenue beat of $0.9MStrong operational efficiencyPositive earnings momentum in cannabis sector

SECTORS INVOLVED

CannabisConsumer DiscretionaryHealthcare

Analysis generated on Mar 12, 2026 at 00:12 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

MariMed Non-GAAP EPS of $2.20 beats by $2.21, revenue of $41.7M beats by $0.9M

RELATED INTELLIGENCE